In regards to " Kraig Biocraft Laboratories, Inc just filed a prospectus, suggesting it plans to soon issue some securities:
Not so, they are required to report certain sales, as these are, as stated:
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-262631
Registration No. 333-255041
PROSPECTUS
KRAIG BIOCRAFT LABORATORIES, INC.
306,124,163 Shares of Class A Common Stock
Pursuant to this prospectus, the selling shareholders identified herein (each a “Selling Shareholder” and, collectively, the “Selling Shareholders”)
are offering on a resale basis, up to 306,124,163 shares of common stock, no par value per share (the “common stock”) of Kraig Biocraft
Laboratories, Inc. (the “Company,” “Kraig,” “we,” “our” or “us”). These shares include: (i) 278,213,449 shares of common stock underlying
secured convertible notes pursuant to that certain securities purchase agreement dated as of January 18, 2022 between the Company and Yorkville
(the “2022 Yorkville Transaction”); (ii) 12,500,000 shares of common stock underlying a warrant issued pursuant to the 2022 Yorkville
Transaction; (iii) 4,285,714 shares underlying a second warrant issued pursuant to the 2022 Yorkville Transaction; (iv) 8,000,000 shares of
common stock underlying a warrant issued pursuant to the transactions contemplated by that certain securities purchase agreement dated as of
March 26, 2021 between the Company and Yorkville (the “2021 Yorkville Transaction”); and (v) 3,125,000 shares of common stock underlying a
warrant issued on December 11, 2020. We are not selling any shares under this prospectus, and we will not receive any proceeds from the sales of
shares by the Selling Shareholders. We will, however, receive the exercise price of the Warrants, if and when such Warrants are exercised for cash
by the holders of such Warrants.
The shares included in this prospectus may be offered and sold directly by the Selling Shareholders in accordance with one or more of the
methods described in the “Plan of Distribution,” which begins on page 29 of this prospectus. To the extent the Selling Shareholders decide to sell
their shares, we will not control or determine the price at which the shares are sold.
Our common stock is listed on OTCQB under the symbol “KBLB.” On April 18, 2022, the last reported sale price of our common stock was
$0.081 per share.
This offering will terminate on the earlier of (i) the date when all of the shares have been sold pursuant to this prospectus or Rule 144 under the
Securities Act of 1933, as amended (the “Securities Act”), and (ii) the date that all of the securities may be sold pursuant to Rule 144 without
volume or manner-of-sale restrictions, unless we terminate it earlier.
Choose your words carefully?
